Medications for Melanoma
Other names: Cancer, Melanoma; Malignant Melanoma; Skin Cancer, Melanoma
About Melanoma: Malignant melanoma is a cancerous skin tumor of the skin cells that produce pigment (melanin).
See also: sub-topics
Drugs Used to Treat Melanoma
The following list of medications are in some way related to, or used in the treatment of this condition.
Drug name | Rx / OTC | Pregnancy | CSA | Alcohol | Reviews | Rating | Popularity |
---|---|---|---|---|---|---|---|
Opdivo | N | 1 review |
10
|
||||
Generic name: nivolumab systemic Drug class: Anti-PD-1 monoclonal antibodies For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information |
|||||||
Intron A | C | N | Add review | Rate | |||
Generic name: interferon alfa-2b systemic Drug class: antineoplastic interferons For consumers: dosage, interactions, side effects For professionals: Prescribing Information |
|||||||
Sylatron | C | N | Add review | Rate | |||
Generic name: peginterferon alfa-2b systemic Drug class: antineoplastic interferons, antiviral interferons For consumers: dosage, interactions, side effects For professionals: Prescribing Information |
|||||||
interferon alfa-2b | C | N | 1 review |
10
|
|||
Generic name: interferon alfa-2b systemic Brand name: Intron A Drug class: antineoplastic interferons For consumers: dosage, interactions, For professionals: A-Z Drug Facts |
|||||||
Yervoy | C | N | Add review | Rate | |||
Generic name: ipilimumab systemic Drug class: anti-CTLA-4 monoclonal antibodies For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information |
|||||||
nivolumab | N | 2 reviews |
5.0
|
||||
Generic name: nivolumab systemic Brand name: Opdivo Drug class: Anti-PD-1 monoclonal antibodies For consumers: dosage, interactions, For professionals: A-Z Drug Facts, AHFS DI Monograph |
|||||||
pembrolizumab | D | N | 1 review |
1.0
|
|||
Generic name: pembrolizumab systemic Brand name: Keytruda Drug class: Anti-PD-1 monoclonal antibodies For consumers: dosage, interactions, For professionals: A-Z Drug Facts, AHFS DI Monograph |
|||||||
dacarbazine | C | N | Add review | Rate | |||
Generic name: dacarbazine systemic Brand name: DTIC-Dome Drug class: alkylating agents For consumers: dosage, interactions, For professionals: A-Z Drug Facts, AHFS DI Monograph, Prescribing Information |
|||||||
Keytruda | D | N | 1 review |
1.0
|
|||
Generic name: pembrolizumab systemic Drug class: Anti-PD-1 monoclonal antibodies For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information |
|||||||
Proleukin | C | N | Add review | Rate | |||
Generic name: aldesleukin systemic Drug class: miscellaneous antineoplastics, interleukins For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information |
|||||||
aldesleukin | C | N | Add review | Rate | |||
Generic name: aldesleukin systemic Brand name: Proleukin Drug class: miscellaneous antineoplastics, interleukins For consumers: dosage, interactions, For professionals: A-Z Drug Facts, AHFS DI Monograph |
|||||||
DTIC-Dome | C | N | Add review | Rate | |||
Generic name: dacarbazine systemic Drug class: alkylating agents For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph |
|||||||
ipilimumab | C | N | Add review | Rate | |||
Generic name: ipilimumab systemic Brand name: Yervoy Drug class: anti-CTLA-4 monoclonal antibodies For consumers: dosage, interactions, For professionals: A-Z Drug Facts, AHFS DI Monograph |
|||||||
temozolomide Off Label | D | N | Add review | Rate | |||
Generic name: temozolomide systemic Drug class: alkylating agents For consumers: dosage, interactions, For professionals: A-Z Drug Facts, AHFS DI Monograph, Prescribing Information Off Label: Yes |
|||||||
peginterferon alfa-2b | C | N | Add review | Rate | |||
Generic name: peginterferon alfa-2b systemic Brand name: Sylatron Drug class: antineoplastic interferons, antiviral interferons For consumers: dosage, interactions, For professionals: A-Z Drug Facts |
|||||||
talimogene laherparepvec | N | Add review | Rate | ||||
Generic name: talimogene laherparepvec systemic Brand name: Imlygic Drug class: miscellaneous antineoplastics For consumers: dosage, interactions, For professionals: A-Z Drug Facts, AHFS DI Monograph |
|||||||
Imlygic | N | Add review | Rate | ||||
Generic name: talimogene laherparepvec systemic Drug class: miscellaneous antineoplastics For consumers: dosage, interactions, side effects For professionals: AHFS DI Monograph, Prescribing Information |
|||||||
Topics under Melanoma
- Melanoma, Metastatic (25 drugs)
Learn more about Melanoma
Micromedex® Care Notes
Symptoms and treatments
Mayo Clinic Reference
Legend
Off Label | This medication may not be approved by the FDA for the treatment of this condition. |
---|
Prescription Only / Over the Counter | |
---|---|
Rx | Prescription Only |
OTC | Over the Counter |
Rx/OTC | Prescription or Over the Counter |
Pregnancy | |
---|---|
A | Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters). |
B | Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women. |
C | Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use in pregnant women despite potential risks. |
D | There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use in pregnant women despite potential risks. |
X | Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use in pregnant women clearly outweigh potential benefits. |
N | FDA has not classified the drug. |
Controlled Substances Act Schedule | |
---|---|
N | Is not subject to the Controlled Substances Act. |
1 | Has a high potential for abuse. Has no currently accepted medical use in treatment in the United States. There is a lack of accepted safety for use under medical supervision. |
2 | Has a high potential for abuse. Has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Abuse may lead to severe psychological or physical dependence. |
3 | Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence. |
4 | Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3. |
5 | Has a low potential for abuse relative to those in schedule 4. Has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 4. |
Alcohol | |
---|---|
X | Interacts with Alcohol. |